Observational studyMedicare & medicaid research review2014

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Franklin Hendrick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.